Document Detail


Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein.
MedLine Citation:
PMID:  14642411     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dietary trans fatty acids/partially-hydrogenated fat has been associated with increased risk of developing cardiovascular disease (CVD), possibly greater than predicted from changes in lipoprotein levels. To explore this issue further potential risk factors were assessed in subjects provided with each of six diets in randomized order containing as the major source of fat: soybean oil, semi-liquid margarine, soft margarine, shortening, traditional stick margarine or butter. Plasma fatty acid profiles reflected diet, with triglyceride and phospholipid subfractions affected to a greater extent than cholesteryl ester. Non-fasting LDL-cholesterol levels were 144+/-27, 141+/-27, 146+/-26, 148+/-30, 151+/-29 and 165+/-31 mg/dl (P<0.001) and total cholesterol/HDL-cholesterol ratios were 5.50+/-1.25, 5.54+/-1.50, 5.69+/-1.29, 5.82+/-1.40, 6.11+/-1.30 and 5.94+/-1.43 (P=0.011), respectively, whereas other lipoprotein levels were not significantly different. Remnant-like particles levels were unaffected by dietary fat, either in the fasting or non-fasting state. Differences in fasting insulin and glucose levels were small and would not be predicted to have a large impact on glucose homeostasis. There was no significant effect of dietary fat type on C-reactive protein levels or blood pressure. These data suggest that, as previously demonstrated, the major CVD risk factor adversely affected by dietary trans fatty acids/partially-hydrogenated fat is LDL-cholesterol levels and total cholesterol/HDL-cholesterol ratios.
Authors:
Alice H Lichtenstein; Arja T Erkkilä; Benoît Lamarche; Ursula S Schwab; Susan M Jalbert; Lynne M Ausman
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Atherosclerosis     Volume:  171     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-12-03     Completed Date:  2004-05-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  97-107     Citation Subset:  IM    
Affiliation:
Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA. alice.lichtenstein@tufts.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biological Markers / blood
Blood Glucose / drug effects,  metabolism
Blood Pressure / drug effects
Boston
Butter
C-Reactive Protein / drug effects,  metabolism
Cardiovascular Diseases / blood,  epidemiology*,  etiology*
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
Cholesterol, VLDL / blood,  drug effects
Dietary Fats / administration & dosage,  blood*
Dose-Response Relationship, Drug
Double-Blind Method
Fasting / blood
Fatty Acids / administration & dosage,  blood
Fatty Acids, Unsaturated / administration & dosage,  blood
Female
Humans
Hydrogenation
Insulin / blood
Male
Margarine
Middle Aged
Phospholipids / blood
Predictive Value of Tests
Risk Factors
Sex Factors
Triglycerides / blood
Grant Support
ID/Acronym/Agency:
HL54727/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Cholesterol, VLDL; 0/Dietary Fats; 0/Fatty Acids; 0/Fatty Acids, Unsaturated; 0/Phospholipids; 0/Triglycerides; 11061-68-0/Insulin; 8029-34-3/Butter; 8029-82-1/Margarine; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiatherothrombotic effects of nicotinic acid.
Next Document:  Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients wit...